Characterization of the antihyperalgesic action of a novel peripheral mu-opioid receptor agonist - Loperamide

被引:80
|
作者
Nozaki-Taguchi, N [1 ]
Yaksh, TL [1 ]
机构
[1] Univ Calif San Diego, Dept Anesthesiol, La Jolla, CA 92093 USA
关键词
hyperalgesia; inflammation; peripheral opiate action;
D O I
10.1097/00000542-199901000-00029
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Preclinical and clinical evidence indicates that locally administered opioid agonists produce an antihyperalgesic effect through peripheral opioid receptors in inflamed tissue. Loperamide, a mu opioid agonist, does not cross the blood-brain barrier and therefore lacks central effects after systemic administration, The authors defined the effects of topical loperamide on a thermal injury-induced hyperalgesia, Methods: In halothane-anesthetized rats, thermal injury was induced by placing the plantar surface of a hindpaw on a hot plate (52.0 +/- 1 degrees C) for 45 s. Loperamide was prepared in a cream emulsion (ADL 2-1294B, 0.5%, 1.7%, and 5.0%). The drug was applied as follows: before or after injury on the injured paw and on a normal paw and after injury on the injured paw of morphine-tolerant rats. Paw withdrawal latency to a radiant heat source was measured to determine the nociceptive threshold. A pharmacokinetic study was performed with the use of' C-14-labeled drug. Results: Thermal injury yielded a significant thermal hyperalgesia, Loperamide, but not the vehicle, posttreatment on theinjured paw resulted in a dose-dependent antihyperalgesic effect, which was reversible with naloxone (1 mg/kg given intraperitoneally), Treatment with loperamide on the normal paw produced short-lasting hypoalgesia, but the effect was not reversible with naloxone. Pretreatment at 1 and 2 but not 4 h with loperamide was effective. A rightward shift of the dose-response curve was observed in rats made tolerant to systemic morphine with subcutaneous morphine pellets. No rats with drug treatment displayed any evident behavior changes (e.g,, loss of corneal or pinna reflexes or change in ambulation). Drug activity in the tissue revealed an elimination half life of 2.3 h and negligible concentration in the blood. Conclusions: Loperamide, a peripherally acting mu opioid agonist, applied topically at the site of inflammation possesses a significant antihyperalgesic action without any systemic side effects.
引用
收藏
页码:225 / 234
页数:10
相关论文
共 50 条
  • [41] Clinical mu-opioid receptor agonist remifentanil inhibits activities of inspiratory neurons in the medulla
    Kaku, Yuki
    Kuwana, Shun-ichi
    NEUROSCIENCE RESEARCH, 2010, 68 : E165 - E165
  • [42] A Novel Pain Management Paradigm: Conformational Studies of the Mu-Opioid Receptor
    Poole, Elizabeth
    Iliff, Hadley
    Edwards, Brady
    Hurst, Dow
    Reggio, Patricia
    BIOPHYSICAL JOURNAL, 2009, 96 (03) : 339A - 339A
  • [43] A novel alternatively spliced isoform of the mu-opioid receptor: functional antagonism
    Gris, Pavel
    Gauthier, Josee
    Cheng, Philip
    Gibson, Dustin G.
    Gris, Denis
    Laur, Oskar
    Pierson, John
    Wentworth, Sean
    Nackley, Andrea G.
    Maixner, William
    Diatchenko, Luda
    MOLECULAR PAIN, 2010, 6
  • [44] PHOTOINACTIVATION OF THE MU-OPIOID RECEPTOR USING A NOVEL SYNTHETIC MORPHICEPTIN ANALOG
    HERBLIN, WF
    KAUER, JC
    TAM, SW
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1987, 139 (03) : 273 - 279
  • [45] Depression of morphine effects and decrease in mu-opioid receptor mRNA level by antisense oligodeoxynucleotide to a mu-opioid receptor.
    Yoshikawa, M
    Kitamura, K
    Taniguchi, T
    Kanai, M
    Iwao, K
    Oka, T
    FASEB JOURNAL, 1996, 10 (06): : 563 - 563
  • [46] Antihyperalgesic effects of loperamide in a model of rat neuropathic pain are mediated by peripheral δ-opioid receptors
    Shinoda, Katsumi
    Hruby, Victor J.
    Porreca, Frank
    NEUROSCIENCE LETTERS, 2007, 411 (02) : 143 - 146
  • [47] HS-731 a novel peripherally restricted MU-opioid agonist with antinociceptive action in acute and inflammatory pain in the rat
    Spetea, M.
    Riba, P.
    Obara, I
    Bileviciute-Ljungar, I
    Guo, Y.
    Przewlocka, B.
    Przewlocki, R.
    Furst, S.
    Schmidbammer, H.
    JOURNAL OF NEUROCHEMISTRY, 2007, 102 : 279 - 279
  • [48] Buprenorphine duration of action:: Mu-opioid receptor availability and pharmacokinetic and behavioral indices
    Greenwald, Mark
    Johanson, Chris-Ellyn
    Bueller, Joshua
    Chang, Yan
    Moody, David E.
    Kilbourn, Michael
    Koeppe, Robert
    Zubieta, Jon-Kar
    BIOLOGICAL PSYCHIATRY, 2007, 61 (01) : 101 - 110
  • [49] NOVEL PEPTIDIC MU-OPIOID ANTAGONISTS - PHARMACOLOGIC CHARACTERIZATION INVITRO AND INVIVO
    KRAMER, TH
    SHOOK, JE
    KAZMIERSKI, W
    AYRES, EA
    WIRE, WS
    HRUBY, VJ
    BURKS, TF
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1989, 249 (02): : 544 - 551
  • [50] Mu-Opioid Receptor Agonist Induces Kir3 Currents in Mouse Peripheral Sensory Neurons - Effects of Nerve Injury
    Stoetzner, Philip
    Spahn, Viola
    Celik, Melih Oe.
    Labuz, Dominika
    Machelska, Halina
    FRONTIERS IN PHARMACOLOGY, 2018, 9